Kim, Byeong-Keuk
Yonsei University · Severance Hospital · Yonsei University Health System
3 papers on CoChatORCID 0000-0003-2493-066X
Most cited papers
- Verified
Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet
Diabetes Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins
Cited by 3,163
- Verified
Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Botros, F. T., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet
Diabetes Treatment and ManagementChronic Kidney Disease and Diabetes
Cited by 638
- Verified
Anti-inflammatory effect for atherosclerosis progression by sodium-glucose cotransporter 2 (SGLT-2) inhibitor in a normoglycemic rabbit model
Lee, S.-G., Lee, S.-J., Lee, J.-J., Kim, J.-S., Lee, O.-H., Kim, C.-K., Kim, D., Lee, Y.-H., Oh, J., Park, S., et al. (2020) · Korean Circulation Journal
Atherosclerosis and Cardiovascular DiseasesDiabetes Treatment and Management
Cited by 75
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free